查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917823

区块链在临床试验市场的应用－2026-2031年预测

Blockchain in Clinical Trials Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计区块链临床试验市场将从 2025 年的 153,392,000 美元成长到 2031 年的 508,430,000 美元，复合年增长率为 22.11%。

区块链在临床试验中的应用市场是指将分散式帐本技术 (DLT) 应用于提升临床研究方法的完整性、安全性和效率。这个专业市场利用区块链的核心架构原则——去中心化、不可篡改性、加密安全性和基于共识的检验——构建了一个检验、透明且防篡改的临床试验数据和流程管理系统。它并非单一产品，而是一个基础技术层，旨在应对多方相关人员、高度监管的临床研究环境中存在的系统性挑战。其最终目标是在整个试验生命週期中提升信任度、协作性和数据品质。

市场对区块链技术的接受度成长源于解决传统临床试验模式中长期存在的挑战的迫切需求。关键的推动因素是对前所未有的资料完整性和可追溯性的需求。区块链不可篡改的帐本为所有试验数据创建了审核、带有时间戳记的监管链，涵盖从患者知情同意书、病例报告表到不利事件报告的所有数据。这项独特特性直接解决了资料篡改、诈欺和无意错误的风险，从而增强了监管申报的有效性和科学的可靠性。此外，该技术有望简化传统上繁琐且分散的资料管理。透过在一个统一、可信任的资讯来源上实现申办者、合约研究组织 (CRO)、研究中心和监管机构之间安全、授权的即时资料共用，区块链减少了资料核对延迟、行政负担和潜在的差异。

核心价值提案在于以病人为中心和增强信任。区块链透过提供安全透明的机制，赋予参与者自主管理知情同意和控制个人健康资讯存取权限的能力。智慧合约是区块链上的自动执行程式码，可以自动化知情同意流程中的某些环节，甚至可以为参与者提供直接且合规的奖励。这种透明度和控制感有望透过建立患者对研究生态系统的信任，从而提高招募率、留存率和整体参与度。

从地理位置来看，北美是开创性和最先进的市场。这主要归功于其成熟的医药研发体系、高度集中的技术创新者，以及对技术试点和讨论持开放态度的法规环境。该地区对资料安全（例如HIPAA）的高度重视及其在全球药物研发中的主导地位，为该领域的早期探索和概念验证（PoC）开发创造了肥沃的土壤。

儘管区块链具有变革性潜力，但其市场在广泛商业部署方面仍面临许多障碍。关键挑战在于，如何将一种新型的去中心化架构深度整合到现有高度复杂且受监管的临床试验工作流程和传统IT系统（例如，电子资料撷取系统（EDC）、临床试验管理系统（CTMS））中。如何在不创建新的资料孤岛的情况下实现互通性，是一个巨大的技术难题。此外，基于区块链的系统的监管路径仍不明朗。 FDA和EMA等监管机构正在寻求明确区块链上的资料审核追踪如何符合现有指南（例如，21 CFR Part 11、ALCOA+原则），以及在去中心化网路中最终由谁承担责任。处理大规模试验资料集的可扩展性和效能，以及资料隐私问题（例如，如何使区块链透明度与GDPR的「被遗忘权」保持一致），也是限制区块链应用的重要阻碍因素。

竞争格局尚不成熟且分散，由成熟的企业技术供应商、专注于区块链领域的新创Start-Ups以及製药公司联盟组成。主要参与者之间的竞争体现在其底层区块链通讯协定的稳健性、能够抽象化技术复杂性的用户友好型应用层的开发，以及与行业相关人员建立战略联盟的能力。成功不仅取决于技术能力，还取决于深厚的临床和监管专业知识，以及透过营运效率和风险规避来展现实际投资回报率的能力。

总之，区块链在临床试验领域的市场目前仍处于探索和试验检验的关键阶段，而非大规模应用阶段。其成长的驱动力源自于一个概念性逻辑：在一个效率低、价值数十亿美元的产业中，人们迫切需要提高透明度、效率和信任度。对于业内人士而言，策略重点应超越理论应用案例，着重解决实际的整合和扩充性挑战，积极与监管机构合作建立评估框架，并量化诸如缩短週期、降低审核成本和提高数据品质等实际价值。成功取决于一种协作式、联盟式的模式，这种模式能够协调所有相关人员的奖励，并展现其在加快新治疗方法上市速度和提高其可靠性方面的实际潜力。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章 按区块链类型分類的临床试验区块链市场

  • 介绍
  • 私人的
  • 民众
  • 联盟
  • 杂交种

第六章：区块链在临床试验市场的应用

  • 介绍
  • 病患资料管理
  • 临床资料交换/共用
  • 药品可追溯性和真实性
  • 智能合约
  • 其他的

7. 区块链在临床试验市场的最​​终用户分布

  • 介绍
  • 製药和生物技术公司
  • 研究和学术机构
  • 其他的

8. 各地区临床试验区块链市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 台湾
    • 其他的

第九章：竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • IBM
  • Microsoft Corporation
  • Oracle Corporation
  • Accenture PLC
  • Consensys Health
  • Bitfury Group Limited
  • FarmaTrust
  • LabTrace
  • Chronicled
  • iSolve

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615808

Blockchain In Clinical Trials Market is projected to expand at a 22.11% CAGR, attaining USD 508.43 million in 2031 from USD 153.392 million in 2025.

The blockchain in clinical trials market represents the application of distributed ledger technology (DLT) to enhance the integrity, security, and efficiency of the clinical research process. This specialized market involves leveraging blockchain's core architectural principles-decentralization, immutability, cryptographic security, and consensus-based validation-to create verifiable, transparent, and tamper-resistant systems for managing clinical trial data and processes. It is not a singular product but rather a foundational technological layer designed to address systemic challenges in multi-stakeholder, highly regulated clinical research environments. The ultimate goal is to improve trust, collaboration, and data quality across the entire trial lifecycle.

Market adoption is driven by the urgent need to address persistent pain points in traditional clinical trial models. A primary catalyst is the demand for unprecedented data integrity and traceability. Blockchain's immutable ledger creates an auditable, time-stamped chain of custody for all trial data-from patient consent forms and case report forms to adverse event reports. This inherent feature directly combats risks of data manipulation, fraud, and unintentional errors, thereby strengthening regulatory submissions and scientific validity. Furthermore, the technology promises to streamline historically cumbersome and siloed data management. By enabling secure, permissioned real-time data sharing among sponsors, contract research organizations (CROs), sites, and regulators on a single, reconciled source of truth, blockchain can reduce reconciliation delays, administrative overhead, and the potential for discrepancies.

A significant value proposition is the enhancement of patient-centricity and trust. Blockchain can empower participants by providing a secure, transparent mechanism for managing their consent and controlling access to their personal health information. Smart contracts-self-executing code on the blockchain-can automate elements of the consent process and even facilitate direct, compliant incentives to participants. This transparency and perceived control have the potential to improve recruitment, retention, and overall engagement by building patient trust in the research ecosystem.

Geographically, North America has been the pioneering and most advanced market, largely due to its mature pharmaceutical R&D sector, high concentration of technology innovators, and a regulatory environment that has shown openness to technological pilots and discussions. The region's strong emphasis on data security (e.g., HIPAA) and its leading role in global drug development have created a fertile ground for initial exploration and proof-of-concept development in this space.

Despite its transformative potential, the market faces substantial barriers to widespread commercial deployment. The primary challenge is the profound complexity of integrating a novel, decentralized architecture into existing, highly complex, and regulated clinical trial workflows and legacy IT systems (EDC, CTMS, etc.). Achieving interoperability without creating new data silos is a significant technical hurdle. Furthermore, the regulatory pathway for blockchain-based systems remains ambiguous. Regulatory agencies like the FDA and EMA require clarity on how data audit trails on a blockchain satisfy existing guidelines (e.g., 21 CFR Part 11, ALCOA+ principles), and who bears ultimate responsibility in a decentralized network. Scalability and performance for handling large-scale trial data, along with concerns over data privacy (e.g., reconciling blockchain's transparency with GDPR's "right to be forgotten"), also present critical adoption constraints.

The competitive landscape is nascent and fragmented, comprising a mix of established enterprise technology providers, specialized blockchain startups, and consortia formed by pharmaceutical companies. Key players compete on the robustness of their underlying blockchain protocol, the development of user-friendly application layers that abstract the technology's complexity, and the ability to form strategic partnerships with industry stakeholders. Success hinges not just on technological prowess, but on deep domain expertise in clinical operations and regulatory affairs, and the ability to demonstrate tangible return on investment through operational efficiencies and risk mitigation.

In conclusion, the blockchain in clinical trials market is at a pivotal stage of exploration and pilot validation rather than mass implementation. Its growth is conceptually supported by the compelling need for greater transparency, efficiency, and trust in a multi-billion-dollar industry burdened by inefficiency. For industry experts, strategic focus must center on moving beyond theoretical use cases to solving practical integration and scalability challenges, actively engaging with regulators to co-create evaluation frameworks, and quantifying the real-world value in terms of reduced cycle times, lower audit costs, and improved data quality. Success will depend on collaborative, consortium-based approaches that align the incentives of all stakeholders and demonstrate that the technology can deliver concrete improvements to the speed and reliability of bringing new therapies to market.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Blockchain in Clinical Trials Market Segmentation

  • By Blockchain Type
  • Private
  • Public
  • Consortium
  • Hybrid
  • By Application
  • Patient Data Management
  • Clinical Data Exchange & Sharing
  • Drug Traceability & Authenticity
  • Smart Contracts
  • Others
  • By End-User
  • Pharmaceutical & Biotech Companies
  • Research & Academic Institutes
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY BLOCKCHAIN TYPE

  • 5.1. Introduction
  • 5.2. Private
  • 5.3. Public
  • 5.4. Consortium
  • 5.5. Hybrid

6. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Patient Data Management
  • 6.3. Clinical Data Exchange & Sharing
  • 6.4. Drug Tracebility & Authenticity
  • 6.5. Smart Contracts
  • 6.6. Others

7. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical & Biotech Companies
  • 7.3. Research & Academic Institutes
  • 7.4. Others

8. BLOCKCHAIN IN CLINICAL TRIALS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Italy
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Taiwan
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. IBM
  • 10.2. Microsoft Corporation
  • 10.3. Oracle Corporation
  • 10.4. Accenture PLC
  • 10.5. Consensys Health
  • 10.6. Bitfury Group Limited
  • 10.7. FarmaTrust
  • 10.8. LabTrace
  • 10.9. Chronicled
  • 10.10. iSolve

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations